Table 1 Characteristics of the Study Participants
Characteristic | Healthy (n = 15) | Type 2 Diabetes (n = 23) |
|---|---|---|
Age (years) | 56.3 ± 2.4 | 59.6 ± 1.5 |
Gender (M/F) | 8/7 | 17/6 |
BMI, (kg/m2) | 25.3 ± 1.2 | 29.7 ± 0.9** |
Diabetes duration, (years) | __ | 12.2 ± 0.9 |
Clinical history | Â | Â |
Smoking, n (%) | 4 (27) | 7 (30) |
Hypertension, n (%) | __ | 11 (48) |
CVD, n (%) | __ | 7 (30) |
Retinopathy, n (%) | __ | 2 (9) |
Nephropathy, n (%) | __ | 3 (13) |
Neuropathy, n (%) | __ | 1 (4) |
Clinical Laboratory Results | Â | Â |
Plasma glucose levels, (mg/dl) | 93.4 ± 2.4 | 221.8 ± 9.5*** |
HbA1c levels, (%) | 4.7 ± 0.1 | 8.6 ± 0.3*** |
Total cholesterol, (mg/dl) | 170.4 ± 8.4 | 178.6 ± 7.2 |
LDL-cholesterol, (mg/dl) | 91.6 ± 3.2 | 107.9 ± 6.5 |
HDL-cholesterol, (mg/dl) | 53.2 ± 1.5 | 51.4 ± 1.7 |
Triglyceride, (mg/dl) | 109.5 ± 9.5 | 127.4 ± 13.2 |
Creatinine, (mg/dl) | 0.77 ± 0.03 | 0.86 ± 0.04 |
Medications | Â | Â |
Insulin, n (%) | __ | __ |
Oral antidiabetics, n (%) | __ | 23 (100) |
   -Rosiglitazone, n (%) | __ | 5 (22) |
   -Sulfonylureas, n (%) | __ | 11 (48) |
   -Metformin, n (%) | __ | 13 (57) |
   -Others, n (%) | __ | 4 (17) |
   -Combination, n (%) | __ | 6 (26) |
ACEIs/ARBs, n (%) | __ | 7 (30) |
Aspirin, n (%) | __ | 19 (82) |
Statins, n (%) | __ | 12 (52) |